Lack of effect of tumor necrosis factor-alpha -308 G/A polymorphism on severity of liver fibrosis in Tunisian hepatitis C virus (HCV)-infected patients;Recherche d'association entre le polymorphisme -308 G/A du gène du facteur nécrosant des tumeurs de type alpha (TNF-α) et la sévérité de la fibrose hépatique chez des patients Tunisiens infectés par le vi

Gastroenterologie Clinique et Biologique

Volumn 34, Issue 4-5, 2010, Pages 297-304

  Bouzgarrou, N ^a   Hassen, E ^a   Gabbouj, S ^a   Schvoerer, E ^b   Ben Mami, N ^c   Triki, H ^d   Chouchane, L ^e  

^a UNIVERSITY OF MONASTIR   (Tunisia)

^b Institute of Virology   (France)

^c LA RABTA HOSPITAL   (Tunisia)

^d PASTEUR INSTITUTE OF TUNIS   (Tunisia)

^e WEILL CORNELL MEDICAL COLLEGE   (Qatar)

Author keywords

[No Author keywords available]

Indexed keywords

TUMOR NECROSIS FACTOR ALPHA;

ADULT; AGED; ARTICLE; COHORT ANALYSIS; CONTROLLED STUDY; DISEASE SEVERITY; FEMALE; GENOTYPE; HEPATITIS C; HUMAN; IMMUNE RESPONSE; LIVER CIRRHOSIS; LIVER FIBROSIS; LIVER INJURY; MAJOR CLINICAL STUDY; MALE; POLYMERASE CHAIN REACTION; PROMOTER REGION; PROTEIN EXPRESSION; PROTEIN POLYMORPHISM; RESTRICTION FRAGMENT LENGTH POLYMORPHISM; SCORING SYSTEM; SINGLE NUCLEOTIDE POLYMORPHISM; TUNISIA;

ADULT; AGED; CASE-CONTROL STUDIES; FEMALE; GENOTYPE; HEPATITIS C, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; POLYMORPHISM, SINGLE NUCLEOTIDE; SEVERITY OF ILLNESS INDEX; TUMOR NECROSIS FACTOR-ALPHA; TUNISIA;

EID: 77953962191     PISSN: 03998320     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.gcb.2010.03.008     Document Type: Article

References (68)

1. Boyer N., Marcellin P. Pathogenesis, diagnosis and management of hepatitis C. J Hepatol 2000, 32:98-112.
2. Rehermann B., Nascimbeni M. Immunology of hepatitis B virus and hepatitis C virus infection. Nat Rev Immunol 2005, 5:215-229.
3. Levrero M. Viral hepatitis and liver cancer: the case of hepatitis C. Oncogene 2006, 25:3834-3847.
4. Thio C.L., Thomas D.L., Carrington M. Chronic viral hepatitis and the human genome. Hepatology 2000, 31:819-827.
5. Bertoletti A., Ferrari C. Kinetics of the immune response during HBV and HCV infection. Hepatology 2003, 38:4-13.
6. Cramp M.E., Carucci P., Rossol S., Chokshi S., Maertens G., Williams R., et al. Hepatitis C virus (HCV) specific immune responses in anti-HCV positive patients without hepatitis C viraemia. Gut 1999, 44:424-429.
7. Pape G.R., Gerlach T.J., Diepolder H.M., Grüner N., Jung M., Santantonio T. Role of the specific T-cell response for clearance and control of hepatitis C virus. J Viral Hepat 1999, 6:36-40.
8. Fabris C., Soardo G., Falleti E., Toniutto P., Vitulli D., Federico E., et al. Relationship among hepatic inflammatory changes, circulating levels of cytokines, and response to IFN-alpha in chronic hepatitis C. J Interferon Cytokine Res 1998, 18:705-709.
9. Bataller R., Brenner D.A. Liver fibrosis. J Clin Invest 2005, 115:209-218.
10. Wynn T.A. Cellular and molecular mechanisms of fibrosis. J Pathol 2008, 214:199-210.
11. Wong G.H., Krowka J.F., Stites D.P., Goeddel D.V. In vitro anti-human immunodeficiency virus activities of tumor necrosis factor-alpha and interferon-gamma. J Immunol 1988, 140:120-124.
12. Nokta M., Matzke D., Jennings M., Schlick E., Nadler P.I., Pollard R. In vivo administration of tumor necrosis factor-alpha is associated with antiviral activity in human peripheral mononuclear cells. Proc Soc Exp Biol Med 1991, 197:144-149.
13. Höhler T., Kruger A., Gerken G., Schneider P.M., Meyer zum Büschenfelde K.H., Rittner C. Tumor necrosis factor alpha promoter polymorphism at position -238 is associated with chronic active hepatitis C infection. J Med Virol 1998, 54:173-177.
14. Lio D., Caruso C., Di Stefano R., Colonna Romano G., Ferraro D., Scola L., et al. IL-10 and TNF-alpha polymorphisms and the recovery from HCV infection. Hum Immunol 2003, 64:674-680.
15. schwabe R.F., Brenner D.A. Mechanisms of liver injury. I. TNF-alpha-induced liver injury: role of IKK, JNK, and ROS pathways. Am J Physiol Gastrointest Liver Physiol 2006, 290:G583-G589.
16. Neuman M.G., Benhamou J.P., Malkiewicz I.M., Akremi R., Shear N.H., Asselah T., et al. Cytokines as predictors for sustained response and as markers for immunomodulation in patients with chronic hepatitis C. Clin Biochem 2001, 34:173-182.
17. Neuman M.G., Benhamou J.P., Malkiewicz I.M., Ibrahim A., Valla D.C., Martinot-Peignoux M., et al. Kinetics of serum cytokines reflect changes in the severity of chronic hepatitis C presenting minimal fibrosis. J Viral Hepat 2002, 9:134-140.
18. Nelson D.R., Lauwers G.Y., Lau J.Y., Davis G.L. Interleukin 10 treatment reduces fibrosis in patients with chronic hepatitis C: a pilot trial of interferon non responders. Gastroenterology 2000, 118:655-660.
19. Ollier W.E. Cytokine genes and disease susceptibility. Cytokine 2004, 28:174-178.
20. Kroeger K.M., Carville K.S., Abraham L.J. The -308 tumor necrosis factor-alpha promoter polymorphism effects transcription. Mol Immunol 1997, 34:391-399.
21. Wilson A.G., Symons J.A., McDowell T.L., McDevitt H.O., Duff GW Effects of a polymorphism in the human tumor necrosis factor alpha promoter on transcriptional activation. Proc Natl Acad Sci USA 1997, 94:3195-3199.
22. Cabrera M., Shaw M.A., Sharples C., Williams H., Castes M., Convit J., et al. Polymorphism in tumor necrosis factor genes associated with mucocutaneous leishmaniasis. J Exp Med 1995, 182:1259-1264.
23. Deghaide N.H., Rodrigues Mde L., Castelli E.C., Mendes-Junior C.T., Figueiredo J.F., Donadi E.A. Tumor necrosis factor region polymorphisms are associated with AIDS and with cytomegalovirus retinitis. AIDS 2009, 23:1641-1647.
24. Miller S.A., Dykes D.D., Polesky H.F. A simple salting out procedure for extracting DNA from human nucleated cells. Nucleic Acids Res 1988, 16:1215.
25. Yamada M., Kakumu S., Yoshioka K., Higashi Y., Tanaka K., Ishikawa T., et al. Hepatitis C virus genotypes are not responsible for development of serious liver disease. Dig Dis Sci 1994, 39:234-239.
26. McGuinness P.H., Bishop G.A., Painter D.M., Chan R., McCaughan G.W. Intrahepatic hepatitis C RNA levels do not correlate with degree of liver injury in patients with chronic hepatitis C. Hepatology 1996, 23:676-687.
27. Napoli J., Bishop G.A., McGuinness P.H., Painter D.M., McCaughan G.W. Progressive liver injury in chronic hepatitis C infection correlates with increased intrahepatic expression of Th1-associated cytokines. Hepatology 1996, 24:759-765.
28. Yoshizawa K., Ota M., Saito S., Maruyama A., Yamaura T., Rokuhara A., et al. Long-term follow-up of hepatitis C virus infection: HLA class II loci influences the natural history of the disease. Tissue Antigens 2003, 61:159-165.
29. Gigi E., Raptopoulou-Gigi M., Kalogeridis A., Masiou S., Orphanou E., Vrettou E., et al. Cytokinem RNA expression in hepatitis C virus infection: Th1 predominance in patients with chronic hepatitis C and Th1-Th2 cytokine profile in subjects with self-limited disease. J Viral Hepat 2008, 15:145-154.
30. Falasca K., Ucciferri C., Dalessandro M., Zingariello P., Mancino P., Petrarca C., et al. Cytokine patterns correlate with liver damage in patients with chronic hepatitis B and C. Ann Clin Lab Sci 2006, 36:144-150.
31. Baroni G.S., Pastorelli A., Manzin A., Benedetti A., Marucci L., Solforosi L., et al. Hepatic stellate cell activation and liver fibrosis are associated with necroinflammatory injury and Th1-like response in chronic hepatitis C. Liver 1999, 19:212-219.
32. Bradham C.A., Plümpe J., Manns M.P., Brenner D.A., Trautwein C. Mechanisms of hepatic toxicity. I. TNF-induced liver injury. Am J Physiol. 1998, 275:G387-G392.
33. Connolly M.K., Bedrosian A.S., Mallen-St Clair J., Mitchell A.P., Ibrahim J., Stroud A., et al. In liver fibrosis, dendritic cells govern hepatic inflammation in mice via TNF-alpha. J Clin Invest 2009, 119:3213-3225.
34. Peng X.D., Dai L.L., Huang C.Q., He C.M., Chen L.J. Correlation between anti-fibrotic effect of baicalin and serum cytokines in rat hepatic fibrosis. World J Gastroenterol 2009, 15:4720-4725.
35. Ozdemir B.H., Bilezikçi B., Haberal M. Hepatic stellate cells in hepatitis C patients: relationship with the development of interstitial fibrosis in renal allografts. Transplant Proc 2009, 41:2838-2840.
36. Naveau S., Emilie D., Balian A., Grangeot-Keros L., Borotto E., Portier A., et al. Plasma levels of soluble tumor necrosis factor receptors p55 and p75 in patients with alcoholic liver disease of increasing severity. J Hepatol 1998, 28:778-784.
37. Tanaka A., Quaranta S., Mattalia A., Coppel R., Rosina F., Manns M., et al. The tumor necrosis factor-alpha promoter correlates with progression of primary biliary cirrhosis. J Hepatol 1999, 30:826-829.
38. Henri S., Chevillard C., Mergani A., Paris P., Gaudart J., Camilla C., et al. Cytokine regulation of periportal fibrosis in humans infected with Schistosoma mansoni: IFN-gamma is associated with protection against fibrosis and TNF-alpha with aggravation of disease. J Immunol 2002, 169:929-936.
39. Ataseven H., Bahcecioglu I.H., Kuzu N., Yalniz M., Celebi S., Erensoy A. Ustundag B.The levels of ghrelin, leptin, TNF-alpha, and IL-6 in liver cirrhosis and hepatocellular carcinoma due to HBV and HDV infection. Mediators Inflamm 2006, 2006:78380.
40. Yee L.J., Tang J., Herrera J., Kaslow R.A., van Leeuwen D.J. Tumor necrosis factor gene polymorphisms in patients with cirrhosis from chronic hepatitis C virus infection. Genes Immun 2000, 1:386-390.
41. Valenti L., Pulixi E., Fracanzani A.L., Dongiovanni P., Maggioni M., Orsatti A., et al. TNF alpha genotype affects TNF alpha release, insulin sensitivity and the severity of liver disease in HCV chronic hepatitis. J Hepatol 2005, 43:944-950.
42. Dai C.Y., Chuang W.L., Lee L.P., Chen S.C., Hou N.J., Lin Z.Y., et al. Associations of tumour necrosis factor alpha promoter polymorphisms at position -308 and -238 with clinical characteristics of chronic hepatitis C. J Viral Hepat 2006, 13:770-774.
43. Rosen H.R., Lentz J.J., Rose S.L., Rabkin J., Corless C.L., Taylor K., et al. Donor polymorphism of tumor necrosis factor gene: relationship with variable severity of hepatitis C recurrence after liver transplantation. Transplantation 1999, 68:1898-1902.
44. Bahr M.J., el Menuawy M., Boeker K.H., Musholt P.B., Manns M.P., Lichtinghagen R. Cytokine gene polymorphisms and the susceptibility to liver cirrhosis in patients with chronic hepatitis C. Liver Int 2003, 23:420-425.
45. Powell E.E., Edwards-Smith C.J., Hay J.L., Clouston A.D., Crawford D.H., Shorthouse C., et al. Host genetic factors influence disease progression in chronic hepatitis C. Hepatology 2000, 31:828-833.
46. Rosen H.R., McHutchison J.G., Conrad A.J., Lentz J.J., Marousek G., Rose S.L., et al. Tumor necrosis factor genetic polymorphisms and response to antiviral therapy in patients with chronic hepatitis C. Am J Gastroenterol 2002, 97:714-720.
47. Goyal A., Kazim S.N., Sakhuja P., Malhotra V., Arora N., Sarin S.K. Association of TNF-beta polymorphism with disease severity among patients infected with hepatitis C virus. J Med Virol 2004, 72:60-65.
48. Romero-Gómez M., Montes-Cano M.A., Otero-Fernández M.A., Torres B., Sánchez-Muñoz D., Aguilar F., et al. SLC11A1 promoter gene polymorphisms and fibrosis progression in chronic hepatitis C. Gut 2004, 53:446-450.
49. Abbas Z., Moatter T., Hussainy A., Jafri W. Effect of cytokine gene polymorphism on histological activity index, viral load and response to treatment in patients with chronic hepatitis C genotype 3. World J Gastroenterol 2005, 11:6656-6661.
50. Chan H.L., Tse A.M., Chim A.M., Wong V.W., Choi P.C., Yu J., et al. Association of cytokine gene polymorphisms and liver fibrosis in chronic hepatitis B. J Gastroenterol Hepatol 2008, 23:783-789.
51. Beretta L., Cappiello F., Moore J.H., Barili M., Greene C.S., Scorza R. Ability of epistatic interactions of cytokine single-nucleotide polymorphisms to predict susceptibility to disease subsets in systemic sclerosis patients. Arthritis Rheum 2008, 59:974-983.
52. Pociot F., Briant L., Jongeneel C.V., Mölvig J., Worsaae H., Abbal M., et al. Association of tumor necrosis factor (TNF) and class II major histocompatibility complex alleles with the secretion of TNF-alpha and TNF-beta by human mononuclear cells: a possible link to insulin-dependent diabetes mellitus. Eur J Immunol 1993, 23:224-231.
53. Stüber F., Petersen M., Bokelmann F., Schade U. A genomic polymorphism within the tumor necrosis factor locus influences plasma tumor necrosis factor-alpha concentrations and outcome of patients with severe sepsis. Crit Care Med 1996, 24:381-384.
54. Wilson A.G., de Vries N., Pociot F., di Giovine F.S., van der Putte L.B., Duff G.W. An allelic polymorphism within the human tumor necrosis factor alpha promoter region is strongly associated with HLA A1, B8, and DR3 alleles. J Exp Med 1993, 177:557-560.
55. Chen Y., Pei J. An assessment of a TNF polymorphic marker for the risk of HCV infection: Meta-analysis and a new clinical study design. Infect Genet Evol 2009, 9:1356-1363.
56. Mitchell S.A., Grove J., Spurkland A., Boberg K.M., Fleming K.A., Day C.P., et al. European Study Group of Primary Sclerosing Cholangitis. Association of the tumour necrosis factor alpha -308 but not the interleukin 10-627 promoter polymorphism with genetic susceptibility to primary sclerosing cholangitis. Gut 2001, 49:288-294.
57. Regev A., Berho M., Jeffers L.J., Milikowski C., Molina E.G., Pyrsopoulos N.T., et al. Sampling error and intraobserver variation in liver biopsy in patients with chronic HCV infection. Am J Gastroenterol 2002, 97:2614-2618.
58. Bedossa P., Dargère D., Paradis V. Sampling variability of liver fibrosis in chronic hepatitis C. Hepatology 2003, 38:1449-1457.
59. Lackner C., Struber G., Liegl B., Leibl S., Ofner P., Bankuti C., et al. Comparison and validation of simple noninvasive tests for prediction of fibrosis in chronic hepatitis C. Hepatology 2005, 41:1376-1382.
60. Stauber R.E., Lackner C. Noninvasive diagnosis of hepatic fibrosis in chronic hepatitis C. World J Gastroenterol 2007, 13:4287-4294.
61. Vardar R., Vardar E., Demiri S., Sayhan S.E., Bayol U., Yildiz C., et al. Is there any non-invasive marker replace the needle liver biopsy predictive for liver fibrosis, in patients with chronic hepatitis?. Hepatogastroenterology 2009, 56:1459-1465.
62. Sheth S.G., Flamm S.L., Gordon F.D., Chopra S. AST/ALT ratio predicts cirrhosis in patients with chronic hepatitis C virus infection. Am J Gastroenterol 1998, 93:44-48.
63. Imperiale T.F., Said A.T., Cummings O.W., Born L.J. Need for validation of clinical decision aids: use of the AST/ALT ratio in predicting cirrhosis in chronic hepatitis C. Am J Gastroenterol 2000, 95:2328-2332.
64. Giannini E., Risso D., Botta F., Chiarbonello B., Fasoli A., Malfatti F., et al. Validity and clinical utility of the aspartate aminotransferase-alanine aminotransferase ratio in assessing disease severity and prognosis in patients with hepatitis C virus-related chronic liver disease. Arch Intern Med 2003, 163:218-224.
65. Giannini E.G., Zaman A., Ceppa P., Mastracci L., Risso D., Testa R. A simple approach to noninvasively identifying significant fibrosis in chronic hepatitis C patients in clinical practice. J Clin Gastroenterol 2006, 40:521-527.
66. Wai C.T., Cheng C.L., Wee A., Dan Y.Y., Chan E., Chua W., et al. Non-invasive models for predicting histology in patients with chronic hepatitis B. Liver Int 2006, 26:666-672.
67. Kanimoto Y., Horiuchi S., Tanase S., Morino Y. Plasma clearance of intravenously injected aspartate aminotransferase isozymes: evidence for preferential uptake by sinusoidal liver cells. Hepatology 1985, 5:367-375.
68. Park G.J., Lin B.P., Ngu M.C., Jones D.B., Katelaris P.H. Aspartate aminotransferase: alanine aminotransferase ratio in chronic hepatitis C infection: is it a useful predictor of cirrhosis?. J Gastroenterol Hepatol 2000, 15:386-390.